These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12696587)

  • 1. Recommended tissue list for histopathologic examination in repeat-dose toxicity and carcinogenicity studies: a proposal of the Society of Toxicologic Pathology (STP).
    Bregman CL; Adler RR; Morton DG; Regan KS; Yano BL;
    Toxicol Pathol; 2003; 31(2):252-3. PubMed ID: 12696587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Society of toxicologic pathology position paper: diet as a variable in rodent toxicology and carcinogenicity studies.
    Nold JB; Keenan KP; Nyska A; Cartwright ME
    Toxicol Pathol; 2001; 29(5):585-6. PubMed ID: 11695576
    [No Abstract]   [Full Text] [Related]  

  • 3. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommended tissue list for histopathologic examination.
    Jacobs A; El Hage J; Hastings K; Jacobson-Kram D; Leighton J; Morse D
    Toxicol Pathol; 2003; 31(5):571. PubMed ID: 14692627
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulatory Forum.
    Peden WM
    Toxicol Pathol; 2016 Dec; 44(8):1069-1071. PubMed ID: 27753636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society of toxicologic pathology position on assessment of hyperplastic lesions in rodent carcinogenicity studies.
    Boorman G; Dixon D; Elwell M; Kerlin R; Morton D; Peters T; Regan K; Sullivan J;
    Toxicol Pathol; 2004; 32(1):124-5. PubMed ID: 14713557
    [No Abstract]   [Full Text] [Related]  

  • 7. STP debate on the desirability of an international mechanism for recognizing qualified toxicologic pathologists.
    Bolon B; Ochoa R; Mann P
    Toxicol Pathol; 2009 Dec; 37(7):992-6. PubMed ID: 19820139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The international symposium on regulatory testing and animal welfare: recommendations on best scientific practices for subchronic/chronic toxicity and carcinogenicity testing.
    Combes R; Schechtman L; Stokes WS; Blakey D
    ILAR J; 2002; 43 Suppl():S112-7. PubMed ID: 12388863
    [No Abstract]   [Full Text] [Related]  

  • 9. Harmonization of animal clinical pathology testing in toxicity and safety studies. The Joint Scientific Committee for International Harmonization of Clinical Pathology Testing.
    Weingand K; Brown G; Hall R; Davies D; Gossett K; Neptun D; Waner T; Matsuzawa T; Salemink P; Froelke W; Provost JP; Dal Negro G; Batchelor J; Nomura M; Groetsch H; Boink A; Kimball J; Woodman D; York M; Fabianson-Johnson E; Lupart M; Melloni E
    Fundam Appl Toxicol; 1996 Feb; 29(2):198-201. PubMed ID: 8742316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection. Letter.
    Schafer KA; Sellers R; Barale-Thomas E
    Toxicol Pathol; 2008 Dec; 36(7):1018-9. PubMed ID: 19126796
    [No Abstract]   [Full Text] [Related]  

  • 11. Society of Toxicologic Pathology position paper on pathology image data: compliance with 21 CFR Parts 58 and 11.
    Tuomari DL; Kemp RK; Sellers R; Yarrington JT; Geoly FJ; Fouillet XL; Dybdal N; Perry R;
    Toxicol Pathol; 2007 Apr; 35(3):450-5. PubMed ID: 17474067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Society of Toxicologic Pathology's position on statistical methods for rodent carcinogenicity studies.
    Morton D
    Toxicol Pathol; 2001; 29(6):670-2. PubMed ID: 11794383
    [No Abstract]   [Full Text] [Related]  

  • 13. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.
    Sistare FD; Morton D; Alden C; Christensen J; Keller D; Jonghe SD; Storer RD; Reddy MV; Kraynak A; Trela B; Bienvenu JG; Bjurström S; Bosmans V; Brewster D; Colman K; Dominick M; Evans J; Hailey JR; Kinter L; Liu M; Mahrt C; Marien D; Myer J; Perry R; Potenta D; Roth A; Sherratt P; Singer T; Slim R; Soper K; Fransson-Steen R; Stoltz J; Turner O; Turnquist S; van Heerden M; Woicke J; DeGeorge JJ
    Toxicol Pathol; 2011 Jun; 39(4):716-44. PubMed ID: 21666103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving carcinogenicity assessment.
    Morton D; Bourcier T; Alden CL
    Toxicol Pathol; 2013 Feb; 41(2):263-70. PubMed ID: 23076039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supplement 1, Toxicologic Pathology, March/April 2004 should be must reading for all pathologists.
    Wagner BM
    Toxicol Pathol; 2004; 32(5):613. PubMed ID: 15603545
    [No Abstract]   [Full Text] [Related]  

  • 16. Best practices for clinical pathology testing in carcinogenicity studies.
    Young JK; Hall RL; O'Brien P; Strauss V; Vahle JL
    Toxicol Pathol; 2011 Feb; 39(2):429-34. PubMed ID: 21297067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory forum opinion piece: the role of the toxicologic pathologist in the postgenomic era: challenges and opportunities.
    Maronpot RR
    Toxicol Pathol; 2012 Oct; 40(7):1082-6. PubMed ID: 22585943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinion on Current Use of Non-Blinded Versus Blinded Histopathologic Evaluation in Animal Toxicity Studies.
    Bolon B; Caverly Rae JM; Colman K; Francke S; Jensen K; Keane K; McInnes EF; Nakano-Ito K; Perry R; Polack E; Regan KS; Romeike A; Young JK; Galbreath EJ
    Toxicol Pathol; 2020 Jun; 48(4):549-559. PubMed ID: 32347786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Society of Toxicologic Pathology position on histopathology data collection and audit trail: compliance with 21 CFR parts 58 and 11.
    Tuomari D; Elliott G; Kulwich B; Yarrington J; Fouillet X; Geoly F; Long P
    Toxicol Pathol; 2004; 32(1):122-3. PubMed ID: 14713556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
    Long GG; Morton D; Peters T; Short B; Skydsgaard M
    Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.